Premium
Chemotherapy in Non‐seminomatous Testicular Tumours Stage I
Author(s) -
EKMAN E. P.,
EDSMYR F.
Publication year - 1981
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1981.tb03163.x
Subject(s) - medicine , stage (stratigraphy) , chemotherapy , lymphadenectomy , disease , adjuvant chemotherapy , testicular cancer , dysgerminoma , survival rate , oncology , surgery , cancer , ovary , paleontology , breast cancer , biology
SUMMARY— Chemotherapy improves the survival rate of patients with disseminated teratoid testicular tumours, but patients without evidence of metastatic spread are not usually given further treatment after retroperitoneal lymphadenectomy because of the high toxicity of most drugs; 10 to 20% of these patients die later with widespread disease. In an earlier series of 24 patients from our hospital the survival rate in stage I disease was below 70%. Since 1 973, when we began to use adjuvant chemotherapy in this group, there have been no relapses.